Oncologists present an optimized strategy against endometrial cancer when "chemo" and immunotherapy no longer work

A new drug, sacituzumab tirumotecán, shows promising results in treating advanced endometrial cancer, significantly improving survival rates compared to standard chemotherapy. Presented at the ESMO Congress, the phase III trial demonstrated a median overall survival increase from 12.1 to 19 months and a 41% reduction in progression or death risk. The drug targets the TROP2 protein, common in endometrial cancer, and has a manageable toxicity profile. Experts believe this treatment could set a new standard for patients with limited options. Additionally, another study suggests pembrolizumab may allow some patients to avoid chemotherapy altogether.